Statin | Statin+ Ezetimibe | Statin+ Evolocumab | p1 | p2 | ||
---|---|---|---|---|---|---|
LDL (mmol/L) | Admission | 3.11 ± 1.02 | 3.24 ± 1.13 | 3.24 ± 0.98 | 0.303 | 0.968 |
Follow-up(1 m) | 1.58 ± 0.44 | 1.96 ± 0.82 | 0.92 ± 0.62 | < 0.001 | < 0.001 | |
Follow-up(3 m) | 1.61 ± 0.49 | 2.10 ± 0.82 | 1.17 ± 0.73 | 0.048 | < 0.001 | |
TG (mmol/L) | Admission | 1.56 ± 1.01 | 1.55 ± 0.72 | 1.57 ± 0.74 | 0.927 | 0.823 |
Follow-up(1 m) | 1.33 ± 0.67 | 1.53 ± 0.70 | 1.29 ± 0.65 | 0.121 | 0.038 | |
Follow-up(3 m) | 1.57 ± 1.13 | 1.66 ± 0.84 | 1.18 ± 0.51 | 0.214 | 0.011 | |
HDL (mmol/L) | Admission | 0.98 ± 0.22 | 1.02 ± 0.22 | 0.99 ± 0.21 | 0.593 | 0.364 |
Follow-up(1 m) | 1.01 ± 0.22 | 1.05 ± 0.25 | 1.03 ± 0.24 | 0.042 | 0.654 | |
Follow-up(3 m) | 1.00 ± 0.18 | 1.00 ± 0.25 | 1.14 ± 0.32 | 0.145 | 0.078 | |
ApoA (g/L) | Admission | 1.08 ± 0.20 | 1.11 ± 0.20 | 1.09 ± 0.17 | 0.785 | 0.240 |
Follow-up(1 m) | 1.17 ± 0.18 | 1.18 ± 0.18 | 1.21 ± 0.19 | 0.223 | 0.390 | |
Follow-up(3 m) | 1.20 ± 0.17 | 1.15 ± 0.20 | 1.25 ± 0.24 | 0.525 | 0.122 | |
ApoB (g/L) | Admission | 0.99 ± 0.21 | 1.00 ± 0.26 | 1.00 ± 0.23 | 0.676 | 0.974 |
Follow-up(1 m) | 0.64 ± 0.16 | 0.70 ± 0.22 | 0.39 ± 0.20 | < 0.001 | < 0.001 | |
Follow-up(3 m) | 0.59 ± 0.15 | 0.75 ± 0.22 | 0.46 ± 0.20 | 0.038 | < 0.001 | |
ApoE (mg/L) | Admission | 41.83 ± 18.16 | 41.60 ± 16.61 | 41.96 ± 12.92 | 0.950 | 0.853 |
Follow-up(1 m) | 33.82 ± 11.29 | 34.46 ± 11.93 | 20.79 ± 9.39 | < 0.001 | < 0.001 | |
Follow-up(3 m) | 32.83 ± 10.80 | 30.44 ± 9.50 | 21.59 ± 8.18 | 0.018 | 0.013 | |
LP(a) (mg/L) | Admission | 331.77 | 310.66 | 330.55 | 0.975 | 0.679 |
Follow-up(1 m) | 281.96 | 283.66 | 271.18 | 0.902 | 0.876 | |
Follow-up(3 m) | 358.29 | 370.88 | 345.92 | 0.951 | 0.867 | |
TCDL (mmol/L) | Admission | 4.97 ± 1.19 | 5.03 ± 1.30 | 5.00 ± 1.16 | 0.799 | 0.884 |
Follow-up(1 m) | 3.16 ± 0.58 | 3.57 ± 0.90 | 2.37 ± 0.74 | < 0.001 | < 0.001 | |
Follow-up(3 m) | 3.18 ± 0.56 | 3.72 ± 1.02 | 2.79 ± 0.72 | 0.074 | < 0.001 |